NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024

Industry: Pharmaceutical Preparations
SEC CIK: 0001426332

SEC filings (opens in a new tab)

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

Q2 2022 vs. Q1 2022

How the institutions holding NGM Biopharmaceuticals Inc changed between Q1 2022 and Q2 2022.

All holders in Q2 2022 All holders in Q1 2022

13F holders of NGM: Q1 2022 compared with Q2 2022
Measure	Q1 2022	Of which not filed for Q2 2022	Q2 2022	Change
Holders	114	2	124	+12
Shares	48.1M	21.6K	47.3M	−701.1K (−1.5%)
Value	$732.8M	$329.0K	$607.3M	−$125.2M (−17.1%)

2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (26)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to NGM in Q2 2022
Institution	Shares	Value	% of portfolio
Rubric Capital Management LP	797,588	$10.2M	0.54%
Partners Group Holding AG	177,255	$2.27M	0.13%
Lexington Partners L.P.	110,428	$1.42M	0.73%
Blackstone Group Inc.	104,432	$1.34M	0.00%
Vident Investment Advisory, LLC	53,194	$682.0K	0.02%
Washington University	44,314	$568.0K	0.21%
Tudor Investment Corp Et Al	39,516	$507.0K	0.01%
Hamilton Lane Advisors LLC	37,503	$481.0K	0.19%
Connor, Clark & Lunn Investment Management Ltd.	36,053	$462.0K	0.00%
XTX Topco Ltd	34,571	$443.0K	0.18%
Dynamic Technology Lab Private Ltd	20,933	$268.0K	0.03%
Common Fund for Nonprofit Organizations	17,725	$227.2K	0.03%
State Board of Administration of Florida Retirement System	15,654	$201.0K	0.00%
ETF Managers Group, LLC	15,271	$196.0K	0.01%
Arrowstreet Capital, Limited Partnership	13,983	$179.0K	0.00%
Principal Financial Group Inc	13,190	$169.0K	0.00%
Susquehanna International Group, LLP	12,619	$162.0K	0.00%
Graham Capital Management, L.P.	12,492	$160.0K	0.01%
Cornercap Investment Counsel Inc	11,499	$147.0K	0.03%
Fox Run Management, L.L.C.	11,128	$143.0K	0.07%
Mirae Asset Global Investments Co., Ltd.	10,974	$141.0K	0.00%
HSBC Holdings PLC	10,325	$132.0K	0.00%
Amundi	7,407	$115.0K	0.00%
Cutler Group LP	100	$1.00K	0.00%
Parallel Advisors, LLC	48	$1.00K	0.00%
Quadrant Capital Group LLC	22	$0	0.00%

Sold out (14)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of NGM in Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
Rho Capital Partners Inc	3,766,666	$57.4M
BVF Inc	955,000	$14.6M
Jacobs Levy Equity Management, Inc	351,943	$5.37M
Norges Bank	95,400	$1.45M
Allianz Asset Management GmbH	48,070	$733.0K
HighVista Strategies LLC	46,243	$705.0K
Squarepoint Ops LLC	38,747	$591.0K
PDT Partners, LLC	38,179	$582.0K
Trexquant Investment LP	25,147	$383.0K
Public Employees Retirement System of Ohio	18,277	$279.0K
Point72 Hong Kong Ltd	2,034	$31.0K
Princeton Global Asset Management LLC	1,600	$24.0K
Bedel Financial Consulting, Inc.	100	$2.00K
Allworth Financial LP	13	$0

Not filed for Q2 2022 yet (2)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NGM in Q1 2022 that haven't filed for Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
Parametric Portfolio Associates LLC	17,629	$269.0K
Amalgamated Financial Corp.	3,933	$60.0K